Key Companies - Epigenetics Drugs & Diagnostic Technologies Industry

The epigenetics drugs and diagnostic technologies market is experiencing significant growth due to the increasing prevalence of cancer and other chronic diseases, as well as the growing demand for personalized medicine. Epigenetics is an emerging field that focuses on the study of changes in gene expression that do not involve alterations to the DNA sequence. The development of epigenetic drugs and diagnostic technologies has the potential to revolutionize the treatment of various diseases, including cancer and autoimmune disorders. The market is highly competitive, with numerous established and emerging players vying for market share. However, regulatory and reimbursement challenges, as well as the high cost of development and commercialization, pose significant obstacles to market growth. Technological advancements and increasing investment in research and development are expected to drive growth in the market in the coming years.

Epigenetics Drugs & Diagnostic Technologies Market

The global is estimated to be valued at US$ 9,408.7 million in 2022 and expected to exhibit a CAGR of 18.8% over the forecast period (2022-2030).

Major Players in the Epigenetics Drugs & Diagnostic Technologies Industry:

Regenacy Pharmaceuticals, Inc.

Regenacy Pharmaceuticals, Inc. is a biotechnology company that was founded in 2016 and is headquartered in Cambridge, Massachusetts, USA. The company is focused on developing small molecule therapeutics for the treatment of diseases that are caused by protein misfolding, such as neurodegenerative disorders and metabolic diseases. Regenacy Pharmaceuticals operates in the United States.

Astex Pharmaceuticals

Astex Pharmaceuticals is a pharmaceutical company that was founded in 1999 and is headquartered in Cambridge, United Kingdom. The company is focused on the discovery and development of small molecule therapeutics for the treatment of cancer and other diseases. Astex Pharmaceuticals operates in the United Kingdom and the United States. In December, 2022 Taiho Oncology, Inc. and Astex Pharmaceuticals, Inc. today announced preliminary data from the Phase 3 ASCERTAIN trial assessing overall and leukemia-free survival in adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML) harboring biallelic TP53 mutations following treatment with oral decitabine and cedazuridine (ASTX727).

4SC AG

4SC AG is a biotechnology company that was founded in 1997 and is headquartered in Planegg-Martinsried, Germany. The company is focused on the discovery and development of small molecule drugs for the treatment of cancer and autoimmune diseases. 4SC AG operates in Germany, Switzerland, and the United States.

CellCentric Ltd.

CellCentric Ltd. is a biotechnology company that was founded in 2004 and is headquartered in Cambridge, United Kingdom. The company is focused on the discovery and development of small molecule drugs for the treatment of cancer and other diseases. CellCentric Ltd. operates in the United Kingdom. In April, 2020 CellCentric signs agreement with the PCCTC for Phase II clinical trial expansion into the US

Celleron Therapeutics Ltd.

Celleron Therapeutics Ltd. is a biotechnology company that was founded in 2009 and is headquartered in Oxford, United Kingdom. The company is focused on the discovery and development of precision medicine therapies for the treatment of cancer and other diseases. Celleron Therapeutics operates in the United Kingdom and the United States. In January, 2023 Celleron Therapeutics and Argonaut Therapeutics have jointly announced the completion of a merger agreement to form IngenOx Therapeutics

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is a pharmaceutical company that was founded in 1887 and is headquartered in New York City, USA. The company is focused on the discovery, development, and commercialization of innovative medicines for the treatment of cancer, cardiovascular disease, and other diseases. Bristol-Myers Squibb Company operates in over 60 countries worldwide. In September, 2022 announced that the U.S. Food and Drug Administration (FDA) approved Sotyktu™ (deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Oryzon Genomics S.A.

Oryzon Genomics S.A. is a biotechnology company that was founded in 2000 and is headquartered in Barcelona, Spain. The company is focused on the discovery and development of epigenetic therapies for the treatment of cancer and neurodegenerative diseases. Oryzon Genomics operates in Spain and the United States. In July, 2022 Oryzon Genomics, S.A., announced the start of a preclinical collaboration with the CMT Research Foundation (CMTRF), a U.S.-based patient-led, non-profit organization treatments and cures for Charcot-Marie-Tooth (CMT) disease, to explore Oryzon’s histone deacetylase 6 (HDAC6) inhibitors.

ChromaMedicine, Inc.

ChromaMedicine, Inc. is a biotechnology company that was founded in 2013 and is headquartered in San Diego, California, USA. The company is focused on the discovery and development of small molecule therapeutics for the treatment of cancer and other diseases. ChromaMedicine operates in the United States.

Epizyme, Inc.

Epizyme, Inc. is a biopharmaceutical company that was founded in 2007 and is headquartered in Cambridge, Massachusetts, USA. The company is focused on the discovery and development of epigenetic therapies for the treatment of cancer and other diseases. Epizyme operates in the United States.

EpiGentek Group Inc.

EpiGentek Group Inc. is a biotechnology company that was founded in 2005 and is headquartered in Farmingdale, New York, USA. The company is focused on the discovery, development, and commercialization of epigenetic research tools and reagents for the life sciences industry. EpiGentek operates in the United States and China.

*Definition-

Epigenetic drugs are medications that target modifications to DNA and associated proteins, potentially altering gene expression. Epigenetic diagnostic technologies involve analyzing changes to these modifications, which can provide insights into disease risk, prognosis, and treatment response.